Session » Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye (2663–2668)
- 11:30AM-11:45AM
-
Abstract Number: 2663
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
- 11:45AM-12:00PM
-
Abstract Number: 2664
Neutrophil-to-Lymphocyte Ratio (NLR) as a Clinically Accessible Marker for Interferon Signatures in Autoimmune Diseases
- 12:00PM-12:15PM
-
Abstract Number: 2665
Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
- 12:15PM-12:30PM
-
Abstract Number: 2666
Rare TNFAIP3 Hypomorphic Variants are a Massively Underestimated Driver of Human Autoinflammatory Disease
- 12:30PM-12:45PM
-
Abstract Number: 2667
Amyloidosis Secondary to Familial Mediterranean Fever: Machine Learning Based Prediction Models
- 12:45PM-1:00PM
-
Abstract Number: 2668
CD14⁺ Myeloid Cells Mediate UVB Photosensitivity in Autoimmune Skin Disease via a Spatially Resolved Inflammatory Circuit